Fw: Ref.: (LML) Hosting a LML session at ILC 2022

 

Leprosy Mailing List – April 29,  2022

 

Ref.:  (LML) Hosting a LML session at ILC 2022

From:  Zhaudat Umerov, Moscow, Russia

 

 

Dear Pieter,

 

       

Indeed, the motto of the Congress is very relevant and reflects the current unresolved problems of the fight against leprosy.

However, if we remember, similar mottoes (in other words) were declared at previous congresses. This indicates a lack of tangible practical progress in many areas, especially in the field of Early Diagnosis and Improved Care. The question arises why is it such a long way from the bench to the bedside.

Of course, there are reasons for this, which are not taken into account by modern management methods, experts, etc. I believe that at the hybrid session of the Congress there is an opportunity to receive very valuable expertise of failures and proposals for the optimal solution of long-standing problems of the fight against leprosy from a large number of experienced participants. Moderators can prepare questions on individual topics and collect the answers for later analysis.

The results of the analysis can be discussed at a hybrid informal session along with the congress and be the basis for more effective cooperation of the activities of individual participants.   Problems whose solution requires the intervention of government agencies can be officially transferred to the instances of individual countries.

Moderators can prepare questions on individual topics and collect answers for further analysis.

The results of the analysis can be discussed at a hybrid informal session along with the congress and be the basis for more effective cooperation of the activities of individual participants. Problems whose solution requires the intervention of government agencies can be officially transferred to the instances of individual countries.

Such a session will not duplicate the work of the congress, but will help to overcome difficulties in achieving the set goals of researchers.

 

Well good luck

 

Zhaudat

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/94131579-c3f2-4beb-b235-bb75b30b9d74n%40googlegroups.com.

Fw: Ref.: (LML) Hosting a LML session at ILC 2022

Leprosy Mailing List – April 18,  2022

 

Ref.:  (LML) Hosting a LML session at ILC 2022

From:  Laila de Laguiche, Curitiba, Brazil

 

 

Dear Pieter,

 

Greetings to all wishing you an excellent Easter!

I appreciate the comments from Ben Naafs in his April 10th email.

Acceptable and gold standard quality of care is an extremely variable attitude in the approach to Hansen's disease in the world today. 

On the one hand, we have countries with horizontal care and others with vertical public health programs. Some countries have compulsory notification and others maintain complete silence. Some countries follow WHO guidelines and others have their own protocol. The diagonal approach with interrelationships between the different levels of health care is not yet widespread and puts many health programs in a difficult situation to adapt, requiring great logistics for the integration of different levels of patient care.

I think the LML group could have a BrainStorming session in order to define a score applicable to any country where the strengths and weaknesses of each type of patient approach in different health services could be objectively demonstrated. Not to punish or classify, but to guide in which direction to go. 

 

It is up to us experts to show what is possible and what is desirable as a gold standard. For example, could the follow-up of patients after discharge from Hansen Virchoviano's disease be a standard in all countries? What are the advantages and disadvantages? Should the discharge be based on medication as it is currently? Or would it be desirable for the discharge to be after the period of vulnerability for leprosy reactions in the years after Multidrug Therapy?

I continue to think about other contributions to this challenge that is huge for LML, maybe too big, but we can't miss this opportunity.

Laila de Laguiche - Curitiba - BRAZIL
Alliance Against Leprosy

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/e4db2d91-c149-46d1-8dbd-1d6567454c7fn%40googlegroups.com.

Fw: Ref.: (LML) Hosting a LML session at ILC 2022

 

 
Leprosy Mailing List – April 17,  2022

 

Ref.:  (LML) Hosting a LML session at ILC 2022

 

From:  Joseph Chukwu, Enugu, Nigeria

 

Dear Pieter,

Warm greetings from Nigeria and many thanks for the excellent service you're offering with LML.

I agree with Ben Naafs that quality of care warrants special attention at the upcoming congress in India. While (active) case-finding has enjoyed so much emphasis at various conferences and meetings, the equally important issue of quality of care has tended to be deprioritised, albeit unwittingly.

Ben's recent LML post thankfully beams the spotlight on the subject. Exactly how best to organise the conversation at the congress is another matter. One way may be a panel discussion where experts with appropriate pedigree field questions on issues of 'quality of patient care' from interested conference participants.

For a robust, transparent and fully honest discussion, I suggest organisers include as panellists not only experts who profess (and defend) current orthodoxy but also people like Joel Almeida, who espouse a 'different' approach.  

 

Happy Easter to all LML readers.

Joseph N. Chukwu

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/250a727e-9a43-47c0-9492-4795a6dcca42n%40googlegroups.com.

Fw: Ref.: (LML) Improved care for LL patients is critical

From: Leprosy Mailing List <leprosymailinglist@googlegroups.com>

Sent: 14 April 2022 14:03
To: Leprosy Mailing List <leprosymailinglist@googlegroups.com>
Subject: Ref.: (LML) Improved care for LL patients is critical

 

 
Leprosy Mailing List – April 14,  2022

 

Ref.:  (LML) Improved care for LL patients is critical

From:  Joel Almeida, London and Mumbai

 

 

Dear Pieter & colleagues,

 

Recurrence rates after MDT are low among regularly treated HD patients in endemic areas but not so among polar LL patients. Further, the absence of skin smear monitoring during treatment tends to delay diagnosis of recurrence until over 5 years from the withdrawal of anti-microbials. LL patients form fewer than 1% of actively detected new cases. But this 1% of new cases accumulates over the years, gets reinfected, and is an important source of transmission. Other patients are not as susceptible to reinfection.

Genomically anergic LL patients with viable bacilli accumulate after MDT (or are re-registered eventually as relapses/other retreatment). In places such as Comoros, they form an important proportion of the currently bacillated cases. That is how transmission to children and others has continued for the past 20 years, despite vigorous active case finding and fixed-duration treatment. By contrast, in places where LL patients were allowed prolonged anti-microbial protection, transmission declined rapidly. This was true in even places that had low incomes at the time (e.g., Uele DRC, Karigiri India, Weifang Shandong China).

 

Recurrence rates among LL patients (including recurrences belatedly diagnosed 15 years or more after withdrawal of anti-microbial protection) can be underestimated greatly by

a) Mixing LL patients with other MB patients in the analysis (just as breast cancer rates among females can be seriously underestimated by mixing them with males in the analysis)

 

b) Stopping follow-up within <5 years after withdrawal of anti-microbials while omitting skin smear monitoring of LL/highly bacillated patients.(In the absence of skin smears recurrences are generally not diagnosed until >5 years after withdrawing anti-microbials).

 

c) Mixing the first five years of follow-up with later years of follow-up in the analysis of recurrence rates. Most recurrences are not diagnosed until >5 years after withdrawal of anti-microbials. Many are diagnosed 10 to 20 years later.

 

Competent & prolonged care for LL patients, including protection against reinfection, is critical to stopping transmission. It is also an important way to reduce suffering, disability and social exclusion of highly bacillated patients. There is no good reason to deny LL patients the respect and care they deserve.

 

 

Best,

 

Joel Almeida

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/d74cca1c-de5c-4d90-b361-18e5ae66368fn%40googlegroups.com.

Fw: Ref.: (LML) Hosting a LML session at ILC 2022

 
Leprosy Mailing List – April 10,  2022

 

Ref.:  (LML) Hosting a LML session at ILC 2022

 

From:  Ben Naafs, Munnekeburen, the Netherlands

 

 

Dear LMLers,

 

We ask you for your suggestions.

 

World Leprosy Congress is nearing, with a timely and appropriate theme: Better Knowledge, Early Diagnosis and Improved Care, for the LML members a near motto, particularly the improved care.

 

The organization has offered us a hybrid session within the regular congress.

We as moderators ask for your suggestions on how we fill in this session. 

 

We also consider a hybrid informal session along with the congress in which we will be able to meet each other, communicate and meet the regular contributors.

 

In these times that freedom of speech and thinking are threatened.  The LML is independent of any government, industry or organisation. It is a free and open forum focused on leprosy in all its aspects where discussions about ideas, and opinions, can take place and questions asked.  The quality of patient care is a core element.

 

How can we bring this into this session? We need your brain.

 

Regards,

 

Ben

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/1a69c868-a696-4c96-b3f2-a853e7932fecn%40googlegroups.com.

Fw: Ref.: (LML) Infolep monthly overview of new publications on leprosy - Apr '22

 

Leprosy Mailing List – April 7,  2022

 

Ref.:  (LML) Infolep monthly overview of new publications on leprosy - Apr '22

From:  Anniek Akerboom, Amsterdam, the Netherlands

 

Dear colleagues, 

Today and tomorrow, April 7 & 8, the Leprosy Research Initiative is organising its annual Spring Meeting. Register for free now and keep up-to-date with leprosy research projects and network with researchers around the globe. Register >>

Last month, the ILEP Conference 2022 on active case-finding and health systems strengthening took place. About 250 people from around the globe participated. If you were not able to attend, the recorded sessions and PowerPoint presentations are available in this folder >>.

American Leprosy Missions (ALM), one of Infolep's valued partners, will award a $40,000 prize in the fourth annual NTD Innovation Prize contest, presented in partnership with NTD NGO Network. Submissions must focus on innovations that leverage digital health and technology to solve issues posed by neglected tropical diseases (NTDs). Applications will be accepted until 30 April at ntdinnovation.org/apply >>.
Call for reviewers: ALM seeks a diverse group of NTD and innovation experts to serve as reviewers for the 2022 NTD Innovation Prize. Learn more and apply >>

Be sure to complete the early-bird registration for the 21st International Leprosy Congress (ILC) by April 30 and send in abstracts before 31 May. Learn more and register >>

Enjoy reading the latest publications on leprosy and have a look at the coming events below. Also, I would be happy to assist you with literature searches on Infolep.

Warm regards,

Anniek Akerboom

Infolep Coordinator
www.leprosy-information.org
a.akerboom@infolep.org
 

 

 

Highlighted

 

Online course: Leprosy - training of health workers on skin-NTDs
World Health Organization . OpenWHO. 2022.
 

Online course: Safety in administering medicines for neglected tropical diseases
World Health Organization. OpenWHO. 2022.
 

The need for an integrated, contextual, and holistic, minimum essential data collection tool for leprosy and lymphatic filariasis disability in India
Anand S, John A, Singh RK. Lepra. Leprosy Review. 2022; 93 (1) : 38-47.
 

Fact Sheet on Intersectionality
Light for the World. 2022.
 

 

 

Leprosy & COVID-19

 

Asymptomatic low pulse oximetry measurements in leprosy patients in the time of COVID-19: Dapsone side effect.
Frade M, Filho F, de Lima A, et al. Revista da Sociedade Brasileira de Medicina Tropical. 2022.
 

Kynurenines in the Pathogenesis of Peripheral Neuropathy During Leprosy and COVID-19.
de Oliveira J, de Athaide M, Rahman A, et al. Frontiers in cellular and infection microbiology. 2022.
 

 

 

New publications

Feel free to contact me to receive full-text versions if these cannot be found through the Infolep portal.

 

Factors influencing the mental wellbeing of persons affected by leprosy in Far-Western Nepal
Pierneef L, van 't Noordende AT, Bista M, et al. Lepra. Leprosy Review. 2022; 93 (1) : 12-25.
 

Knowledge and attitudes on leprosy of healthcare workers in a tertiary government hospital in the Philippines
Chavez CP, Lopez MHP, de Guia CE, et al. Lepra. Leprosy Review. 2022; 93 (1) : 26-37. 
 

Initiatives to address leprosy as a human rights issue through the mandate of UN Special Rapporteur: Achievements and challenges
Nanri T, Zhang F. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2022; 16 (3) : e0010201.
 

United for dignity: four strategic shifts to get to zero leprosy by 2030.
Warusavithana S, Osman M, Atta H, et al. Eastern Mediterranean health journal. 2022; 28 (2) : 93-94. 
 

Ethical considerations for leprosy researchers
Butlin CR, Peters RMH. Lepra. Leprosy Review. 2022; 93 (1) : 2-11.
 

The Impact of Leprosy on the Quality of Life of Patients Undergoing Treatment
Gomes MEO, Assis FSD, Alves de Oliveira A, et al. Editora e Distribuidora Educacional. Journal of Health Sciences. 2022; 24 (1) : 06-11. 
 

High yield of retrospective active case finding for leprosy in Comoros.
Ortuño-Gutiérrez N, Mzembaba A, Baco A, et al. PLoS neglected tropical diseases. 2022; 16 (3) : e0010158.
 

Leprosy as immune reconstitution inflammatory syndrome in patients living with HIV: Description of French Guiana's cases over 20 years and systematic review of the literature.
Mouchard A, Blaizot R, Graille J, et al. PLoS neglected tropical diseases. 2022; 16 (3) : e0010239. 
 

Socio-demographic factors, treatment-seeking behaviours and common clinical presentations of leprosy patients in Anuradhapura, Sri Lanka
Weerakoon H, Banduwardana H, Ranawaka R, et al. Sri Lanka Journals Online (JOL). Anuradhapura Medical Journal. 2022; 16 (1) : 6. 
 

Mycobacterium leprae and Mycobacterium lepromatosis infection. A report of six multibacillary cases of leprosy in Dominican Republic.
Fernández J, Pou-Soarez V, Arenas R, et al. Japanese journal of infectious diseases. 2022.
 

Comportamento epidemiológico da hanseníase em vários países da América Latina, 2011-2020.
Cáceres-Durán M. Revista panamericana de salud publica = Pan American journal of public health. 2022.
 

Perfil epidemiológico da Hanseníase em uma cidade do semiárido baiano, Guanambi, entre os anos de 2001 a 2021
Oliveira MAS, Júnior RCG. South Florida Publishing LLC. Archives of Health. 2022; 3 (2) : 204-210. 
 

Itinerários terapêuticos da hanseníase em Sergipe, Brasil: entre os anos de 2016-2020
Santos GVDS, Santos AMDCD, Silva LMD, et al. Research, Society and Development. 2022; 11 (3) : e58611326760.
 

Perfil Epidemiológico da Hanseníase na Bahia no Período de 2010 a 2020
Oliveira LDOE, Rodrigues da Costa Barros I, Siega AC, et al. Research, Society and Development. 2022; 11 (4) : e16911427228. 
 

Case detection and management of mobile leprosy in Baoan District, Shenzhen : A retrospective analysis
Ye Y, Huang Z, Huang Y, et al. Research Square Platform LLC. 2022.
 

Karo Batak Local Architecture with its Personal Character to Indonesian National Resilience
Tarigan NP, Siregar C, Witono PH. International Journal of Disabilities and Social Inclusion. 2022.

 

Family-based intervention for prevention and self-management of disabilities due to leprosy, podoconiosis and lymphatic filariasis versus usual care in Ethiopia: study protocol for a cluster-randomised controlled trial.
Noordende A, Aycheh M, Moges N, et al. BMJ open. 2022; 12 (3) : e056620. 
 

Somalia tackles leprosy and visceral leishmaniasis
Bagcchi S. Elsevier BV. The Lancet Infectious Diseases. 2022; 22 (4) : 454.
 

Community intervention programmes with people affected by leprosy: Listening to the voice of professionals.
Martos-Casado G, Vives-Cases C, Gil-González D. PLoS neglected tropical diseases. 2022; 16 (3) : e0010335. 
 

Determinants of patients' delay with disability in the diagnosed leprosy cases in the three major states of India: A case-control study
Govindarajulu S, Muthuvel T, Lal V, et al. Scientific Scholar. Indian Journal of Dermatology, Venereology and Leprology. 2022.
 

Adherence, physical limitation and social participation in leprosy patients in a high-complexity hospital
Cavalheiro AH, Frade MAC, Ungari AQ. Research Square Platform LLC. 2022.
 

Nutritional Status of Patients With Leprosy Attending a Tertiary Care Institute in North India
Jindal R, Nagrani P, Chauhan P, et al. Cureus, Inc.. Cureus. 2022.
 

Diagnostic Value of Neutrophil-to-Lymphocyte Ratio, Lymphocyte-to-Monocyte Ratio, and Platelet-to-Lymphocyte Ratio in the Diagnosis of Erythema Nodosum Leprosum: A Retrospective Study.
Tanojo N, Damayanti D, Utomo B, et al. Tropical medicine and infectious disease. 2022.
 

Innovative mapping of skin sensitivity by monofilaments to record the diagnosis and therapeutic follow-up of leprosy.
Filho F, Lima F, Frade M. Revista da Sociedade Brasileira de Medicina Tropical. 2022.
 

Using Omics to Study Leprosy, Tuberculosis, and Other Mycobacterial Diseases.
Ahamad N, Gupta S, Parashar D. Frontiers in cellular and infection microbiology. 2022.
 

Application of Droplet Digital PCR to Detection of Mycobacterium tuberculosis and Mycobacterium leprae Infections: A Narrative Review.
Fan Y, Chen J, Liu M, et al. Infection and drug resistance. 2022.
 

Protective Efficacy of BCG Vaccine against and Non-Tuberculous Mycobacterial Infections.
Orujyan D, Narinyan W, Rangarajan S, et al. Vaccines. 2022.
 

Mycobacterium leprae induces Schwann cell proliferation and migration in a denervated milieu following intracutaneous excision axotomy in nine-banded armadillos.
Ebenezer G, Pena M, Daniel A, et al. Experimental neurology. 2022.
 

Retraso en el diagnóstico de lepra – Estudio multicéntrico y multinaciones en asia
Post E, Brandsma W, Wagenaar I, et al. Revista de leprología. 2021; 33 (2) : 121-131. 
 

Creating communities of care: Sex estimation and mobility histories of adolescents buried in the cemetery of St. Mary Magdalen leprosarium (Winchester, England)
Filipek KL, Roberts CA, Montgomery J, et al. Wiley. American Journal of Biological Anthropology. 2022.
 

Fenómeno de Lucio: reporte de caso
Aguilar Aguilar N, Sandí Salazar G, Muñoz Mora P. Revista Medica Sinergia. Revista Medica Sinergia. 2022; 7 (2) : e761.
 

Leprosy: A clinical review
Gomes AP, Miguel PSB, Martins e Mafra FB, et al. Universidade de Estado do Rio de Janeiro. Brazilian Journal of Health and Biomedical Sciences. 2022; 20 (2) : 151-160.

 

 

 

Events

 

Leprosy Research Initiative Spring Meeting
7-8 Apr 2022 | Virtual
 

ALM NTD Innovation Prize
Applications accepted Apr 1 - 30 2022
 

NNN Conference
13-15 Sep 2022
Kathmandu & Virtual

 

COR-NTD Annual Meeting 2022
4 - 5 Oct | Virtual
 

21st International Leprosy Congress
>> Early-bird registration by 30 April
>> Abstract submission by 31 May
8-11 Nov 2022
Hyderabad & Virtual

 

 

Links

 

Info Hansen - A innovative hub for knowledge sharing about Hansen's Disease
 

ALLF - Official website of the Association des Léprologues de Langue Française
 

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in leprosy to share ideas, information, experiences and questions
 

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)

 

ILEP newsletter archive

GPZL newsletter archive

WHO Goodwill Ambassador's Leprosy Bulletin

Leprosy Review

Leprosy Review Repository (1928-2001)

Fontilles Revista de Leprología

Indian Journal of Leprosy

Hansenologia Internationalis

 

GDPR & the Infolep newsletter

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our privacy statement and mailing list.

Infolep sends out monthly e-mails with an overview of recent publications on leprosy and related issues. The purpose of this activity is to keep subscribers up to date.

Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can update your preferences or unsubscribe from this list at any time.

 

Send us an email

 

Visit our website

 

Facebook

 

Twitter

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/6d169f73-05bf-49fd-9eb1-0b26fb92bce4n%40googlegroups.com.

Fw: Ref.: (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 108, March 2022

 

Leprosy Mailing List – April  7,  2022

 

Ref.:  (LML) WHO Goodwill Ambassador's Leprosy Bulletin NO. 108, March 2022

From:  Takahiro Nanri, Tokyo, Japan

 

Dear Dr. Schreuder and Friends,  

Warm greetings from Sasakawa Health Foundation/Sasakawa Leprosy (Hansen's Disease) Initiative in Tokyo.

We have issued WHO Goodwill Ambassador's Leprosy Bulletin NO. 108 March 2022 Initiative in Asia today. In this issue, we feature:

MESSAGE FROM THE AMBASSADOR

Leprosy, also known as Hansen's disease, is an ancient infectious disease that has challenged humanity across all national, philosophical, racial, and religious borders. With the universality of leprosy's challenges in mind, I visited the United Nations Commission on Human Rights in Geneva for the first of many times in 2003... Read More

INTERVIEW 
Laws should reflect the values of society  - Saber Hossain Chowdhury, Member of Parliament (MP), Bangladesh/ Honorary President, Inter-Parliamentary Union (IPU)

Saber Hossain Chowdhury is an incumbent Member of Parliament (MP) in Bangladesh. From 2014 to 2017, he was President of the Inter-Parliamentary Union (IPU), which aims to promote peace, democracy, and sustainable development around the world.  Read more

VIEWPOINT 
Reflections on 16 years of APAL - G. Venu Gopal, CEO, Association of People Affected by Leprosy (APAL)

Association of People Affected by Leprosy (APAL) is a national organization in India with a community-based network spread across 16 states and covering 800 colonies. APAL's plan and main aims are to make sure that persons affected by leprosy and their families become very strong economically and socially, Read more

LETTER 
Current status of persons affected by leprosy in Nepal  - Amar Bahadur Timalsina, Executive Director, IDEA Nepal

I am attempting to use words to give you a picture of the conditions of persons affected by leprosy in Nepal. Not surprisingly, I wish to show both the achievements of the last 10 years and newly emerging challenges. Read more

INITIATIVE NEWS
"Don't forget leprosy" campaign boosts messaging in the weeks around World Leprosy Day 

Diversion of resources, movement restrictions, and other measures implemented during the COVID-19 pandemic have disrupted leprosy services and increased burdens on already vulnerable persons affected by leprosy.  Read more

WISH LIST 
Kerstin Beise, Chair, Yayasan Dedikasi Tjipta Indonesia (YDTI)

For each issue, the Leprosy Bulletin asks a person affected by leprosy or an individual involved in leprosy-related work for two to three things that they wish could happen. Originally from Germany, Kerstin Beise has been living in Indonesia since 1998...  Read more

SPOTLIGHT
Yayasan Dedikasi Tjipta Indonesia (YDTI)

YDTI is a non-governmental organization founded by Kerstin Beise that started out in 2016 as a representative office of a Netherlands-based consultancy cooperative called Dare This.  Read more

BACK ISSUES

We hope that you would enjoy reading the latest Leprosy Bulletin.

Takahiro NANRI, Ph.D.
Executive Director, Sasakawa Health Foundation

*********************************************************
Sasakawa Leprosy (Hansen's Disease) Initiative
Sasakawa Health Foundation
Tel：81-3-6229-5377, Fax：81-33-6229-5388
email: hansen@shf.or.jp
website: https://sasakawaleprosyinitiative.org/,  https://www.shf.or.jp
********************************************************* 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/f46d2390-fde6-4354-9180-5ca9d06c6ec9n%40googlegroups.com.

Fw: Ref.: (LML) ILC 2022 - an update

 

 
Leprosy Mailing List – April 5,  2022

 

Ref.:  (LML) ILC 2022 - an update

From:  P. Narasimha Rao, Hyderabad, India

 

 

Dear Pieter,

 

 

I am happy to share with you a few updates of  ILC 2022.

 

As you are aware the theme of 21st International Leprosy Congress (ILC) is Better Knowledge, Early Diagnosis and Improved Care. 

 

While the Congress is being organized by IAL and IADVL with the support of  Central Leprosy Division (CLD) NLEP, MoH&FW, Govt of India; under the auspices of International Leprosy Association (ILA), I am happy to share the good news that ILEP, LEPRA, Sasakwa leprosy initiative and TLMI have agreed to be the official partners of this congress. I am sure a number of other stakeholders too would join in as we have already written to / in communication with them. People affected by leprosy are also going to be an important part of this congress. 

 

The abstract submission portal at the website  is active now. For this conference we are planning to have two additional categories of presentation, apart from Oral free paper and poster presentation which are:  Award paper sessions for student trainees and  a Short video presentation. (Please visit the ILC website https://www.ilc-india2022.com for details). Abstracts are invited for both these categories too. 

 

We got a good number of volunteers for Abstract mentor program, thanks to LML for announcing it.  The response to AMP has been good so far and it is likely to pick up further in the  coming weeks. 

 

We have made a few changes in the way the presentation mode can be chosen for abstract submission. A new category of 'Either' has been added as the third option, in addition to the  'physical presentation'  and 'web-based virtual presentation' choices.  Of course, the presenter has to decide about the mode, within a couple weeks of the abstract being accepted. 

 

I am happy to announce that we are planning to develop an 'ILC 2022 mobile app exclusively for this congress. Hopefully it will be ready by the last week of June and would make navigation of the ILC website and congress programme details easier. 

 

As the ILC 2022 is in hybrid mode, there will be more than 60-70 hours of web-based sessions which can be  viewed by all those who register as web/ E delegates. In addition they will have access to  the live transmission of most of the physical events, including plenary sessions. An exclusive 'award paper session' is being planned for e-delegates to encourage participation of student trainees and young scholars online. 

 

As of now IADVL and IAL association have announced a limited number of  registration scholarships/ cash scholarships to its members for attending the congress. Some of these scholarships will be open for any delegate to apply. We hope to see more such scholarships announcements  in the next few months. 

 

Registrations for the  congress are trickling in and we hope to see many more in the next few months. We look forward to the continued support, registration and participation of LML members in this  congress.

 

Best regards, 

 

P. Narasimha Rao, MD, D.D, PhD

Organising Secretary, 

21st International Leprosy Congress. 2022

 

Mobile-+91-9849044898

Email: dermarao@gmail.com

www.ial-leprosy.org

www.ilc-india2022.com

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/4da15e61-efc5-4405-9029-5201ea1d760an%40googlegroups.com.